This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Primary Objective:The primary goal of this phase II clinical trial is to evaluate the clinical effectiveness of inhaled nitric oxide for the treatment of acute vaso-occlusive pain crisis in pediatric patients with sickle cell disease. The primary outcome measure for this study is change in pain score from baseline to 16 hours, which will be assessed using a 10 cm visual analog scale (VAS).
Showing the most recent 10 out of 463 publications